VYNE Therapeutics Inc. (VYNE)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 02:11PM EDT. Market open.
| Previous close | 2.3500 |
| Open | 2.3100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.2401 - 2.3600 |
| 52-week range | 1.6700 - 8.7300 |
| Volume | |
| Avg. volume | 104,275 |
| Market cap | 32.991M |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.7200 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.58 |
Simply Wall St.VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
GlobeNewswireVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & In
Simply Wall St.VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
VYNE Therapeutics ( NASDAQ:VYNE ) Full Year 2023 Results Key Financial Results Net loss: US$27.9m (loss narrowed by 18...
© 2024 Yahoo. All rights reserved.